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ABSTRACT
TNF-LIKE WEAK INDUCER OF APOPTOSIS (TWEAK): NOT SO WEAK AFTER ALL

Joseph D. McMillan IV
September 9th, 2016
Background: Tumor necrosis factor (TNF)-like weak inducer of apoptosis
(TWEAK) is a proinflammatory cytokine belonging to the TNF super family.
TWEAK produces a variety of cellular responses through the binding to fibroblast
growth factor inducible 14 (Fn14), a member of TNF receptor superfamily.
Although Fn14 lacks a death domain, TWEAK has been found to induce
apoptosis in some cell types by perturbing the activity of certain pathways such
as TNF-receptor signaling. TWEAK is also known to regulate proliferation and
differentiation of myogenic cells. We have previously reported that the TWEAKFn14 system causes skeletal muscle wasting both in vitro and in vivo. In addition,
it has been reported that TWEAK is a mediator of atrophy in disuse conditions
such as denervation. However, it remains unknown whether TWEAK can affect
the viability of muscle cells.
Hypothesis: TWEAK induces oxidative stress and cell death in myotube
cultures.
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Methods: We used primary myogenic cells and biochemical assays to study the
effects of recombinant TWEAK protein on the survival of cultured mouse primary
myotubes.
Results: Our results demonstrate that TWEAK reduces myotube viability in a
dose-dependent manner evident by increased levels of lactate dehydrogenase
(LDH) in culture supernatants. Furthermore, we have found that the levels of
cleaved poly (ADP-ribose) polymerase (PARP) and cleaved (activated) caspase3 are increased upon treatment with TWEAK. TWEAK also induces oxidative
stress in cultured myotubes. A general antioxidant, N-acetyl-L-cysteine (NAC),
partially blocked TWEAK-induced cytotoxicity in cultured myotubes.
Conclusions: Our results provide initial evidence that in addition to causing
atrophy, TWEAK can also diminish skeletal muscle mass by inducing oxidative
stress, which diminishes the survival of myofibers in catabolic conditions.
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CHAPTER 1: INTRODUCTION
Skeletal muscle is the most abundant tissue of the human body, which provides
structural support, enables the body to maintain posture, and ensures basic
functions such as locomotion, respiration, energy storage, and whole body
metabolism. Skeletal muscle is also a highly plastic tissue. Skeletal muscle
undergoes hypertrophy in response to various physiological stressors, such as
weight bearing and exercise. Skeletal muscle remodels by activating multiple
signaling pathways to reprogram gene expression to sustain muscle mass,
energy metabolism, and performance. By contrast, loss of skeletal muscle mass
(i.e. muscle atrophy/wasting) is a devastating consequence of a large number of
chronic disease states and several other conditions such as: starvation,
denervation, immobilization, and aging 1,2. However, there is currently no drug
approved for the prevention or treatment of muscle wasting, partly because the
mechanisms of muscle growth/hypertrophy and atrophy remain poorly
understood 3. Over the past several years, our laboratory has identified the
cytokine, TWEAK, as a potent mediator of muscle wasting in many conditions.
The mechanisms by which TWEAK induces skeletal muscle wasting remain less
understood. The major goal of my thesis was to investigate the mechanisms of
action of TWEAK in skeletal muscle with a focus on oxidative stress and survival
of muscle cells. In the following sections, I provide a succinct description of the
processes involved in the regulation of skeletal muscle mass.
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Myogenesis
Myogenesis is a highly coordinated process by which skeletal muscle is formed
during embryonic development (Figure 1.1). The process of myogenesis is also
required for regeneration of injured myofibers and skeletal muscle growth in
response to anabolic cues4,5. During embryonic development, skeletal muscle
originates from the paraxial mesoderm, forming somites, then the
dermomyotome, and finally the myotome. Myoblasts undergo frequent cell
divisions and eventually fuse together leading to the formation of multinucleated
myotubes/myofibers6. In postnatal skeletal muscle, a fraction of the muscle
progenitor cells, known as satellite cells, enter quiescence and reside underneath
the basal lamina of adult muscle fibers 5,7. Skeletal muscle is a terminally
differentiated tissue, yet it possesses a remarkable capability to regenerate in
response to injury, an ability attributable to satellite cells. Upon injury, satellite
cells reenter the cell cycle, proliferate, and subsequently differentiate into
myoblasts. Myoblasts differentiate into myocytes, which fuse with injured
myofibers to complete the process of myofiber regeneration

5,8.

While a vast

majority of activated satellite cells progress into the myogenic lineage and
contribute to muscle repair, a very small proportion of them undergo self-renewal
and return to quiescence to replenish the pool of satellite cells for future rounds
of skeletal muscle repair.
Skeletal muscle formation is regulated by the sequential expression of a
number of myogenic transcription factors. Paired-box (Pax) 3 and Pax7
transcription factors are involved in early lineage specification 4. Pax7 is almost
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exclusively expressed in satellite cells, which are critical for the self-renewal and
maintenance of their myogenic potential in adult skeletal muscle 8. Following
specification to the myogenic lineage, the levels of Pax7 are reduced, whereas
the levels of Myf5 and MyoD transcription factors are increased, which results in
the formation of proliferating myoblasts. After several rounds of cell division,
myoblasts differentiate into myocytes, which express the late myogenic
regulatory factors (MRFs), myogenin (MyoG) and MRF4. Myocytes then fuse
with one another to form multinucleated myotubes/myofibers, which express both
the late MRFs and the specific muscle proteins that are required for maintenance
of contractile function and metabolic activity 8,9. Additional heterogeneity
develops in the form of skeletal muscle fiber types that vary in their metabolic
capacity and protein expression in accordance with the context-dependent
function of the specific muscle.

Signaling mechanisms regulating skeletal muscle mass
In the context of acute, everyday stressors, such as weight bearing and exercise,
skeletal muscle responds by activating multiple signaling pathways that promote
the expression of genes that alter muscle mass, energy metabolism, and
performance to meet environmental demands. In similar fashion, as the
environmental demands change due to prolonged inactivity or chronic disease
states, the skeletal muscle responds by initiating signaling cascades that lead to
muscle atrophy or wasting in a context-dependent manner10. Skeletal muscle
mass is maintained through a delicate balance between the rate of protein
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synthesis and degradation 2,11. Resistance exercise, hormones, and nutritional
uptake increase the rate of protein synthesis resulting in muscle hypertrophy
1,12,13.

IGF1/PI3K/Akt/mTOR is an important signaling pathway which increases

protein synthesis leading to skeletal muscle hypertrophy 14,15. Activation of this
pathway also inhibits muscle protein degradation through distinct mechanisms
16,17.

While activation of canonical TGF-β family members (e.g. myostatin and

activin), which function through activin receptors and activation of transcription
factors Smad2/3, causes muscle wasting 18, recent studies have provided strong
evidence that the activation of the bone morphogenetic protein (BMP)-Smad1/5/8
signaling pathway induces muscle growth 19-21. Activation of the BMP-Smad1/5/8
pathway also counters skeletal muscle wasting in many catabolic states

22,23

.

Interestingly, preliminary studies in our lab suggest that transforming growth
factor beta-activated kinase 1 (TAK1) is an important regulator of both
PI3K/Akt/mTOR and (BMP)-Smad1/5/8 signaling and that these two pathways
may cross-talk through TAK1 to promote muscle growth.
The ubiquitin-proteasome system (UPS) is a major proteolytic mechanism
in skeletal muscle. Proteases such as caspases and calpains may also be
required for initial cleavage of the myofibrillar components, thereby accelerating
disassembly and degradation by the UPS 24,25. The activity of UPS is increased
in response to many extracellular stimuli such as inflammatory cytokines, tumorderived factors, and oxidative stress. Additionally, the UPS is also activated in
many disuse conditions such as denervation, immobilization, and unloading. A
number of E3 ubiquitin ligases such as: MuRF1, MAFBx (Atrogin-1), Nedd4.1,

4

and MUSA1 have now been identified which cause proteolytic degradation of
thick and thin filament proteins in skeletal muscle

20,26,27.

While excessive

activation of the autophagy-lysosomal pathway can lead to muscle wasting 1,13,17,
accumulating evidence suggests that some level of autophagy is essential to
maintaining skeletal muscle health and function. Inhibition of basal autophagy
leads to myopathy and excessive loss of muscle mass due to accumulation of
dysfunctional organelles, dysfunctional proteins, and oxidative stress 28-30. The
activity of UPS and/or autophagy is regulated through the activation of a number
of signaling pathways such as PI3K/Akt/mTOR, p38MAPK, AMP-activated
protein kinase (AMPK), and nuclear factor-kappa B (NF-B) which function
through modulating the activity of various transcriptional regulators

1,13,31-36

.

Furthermore, it is also now evident that changes in the mitochondrial content,
integrity, and function also play critical roles in the regulation of muscle mass
1,37,38.

TWEAK-Fn14 system
TNF-like weak inducer of apoptosis (TWEAK) is a member of the TNF
superfamily (TNFSF). The TNFSF is a 19-member group of type II
transmembrane proteins that are involved in the regulation of a plethora of
normal cellular responses including: immune response, hematopoiesis, and
morphogenesis39,40. However, the TNFSF has also been implicated in many
disease states such as: tumorigenesis, transplant rejection, septic shock, viral
replication, bone resorption, and cachexia39,41 among others. TWEAK is
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expressed as a 249 amino acid (aa) type II transmembrane protein and similar to
other members of the TNFSF can be proteolytically cleaved into a soluble,
biologically active 156 aa cytokine42. Structurally, soluble TWEAK can be
characterized as an anti-parallel β-sheet that binds to the fibroblast growth factor
inducible-14 receptor (Fn14) as a homotrimer42,43. Between the trimers, there are
grooves that serve as the binding sites for the Fn14 receptor43.
The characterization of a TNF-receptor super family (TNFRSF) member
with TWEAK-binding activity was initially reported by Wiley et al. in 200143,44.
Originally it was given the name TweakR, but the predicted protein sequence
was found to be identical to the Fn14 receptor discovered in 1999 by MeighanMantha et al45. TWEAK binds exclusively to the Fn14 receptor and the Fn14
receptor does not bind any other member of the TNFSF43. The Fn14 receptor is a
129 aa type I transmembrane protein and is the smallest member of the
TNFRSF43,44. In the 53 aa extracellular ligand-binding domain, the Fn14 receptor
contains a single cysteine-rich subdomain in contrast to other members of the
TNFRSF that contain three or four43. The intracellular signaling capacity of Fn14
relies on the 29 aa cytoplasmic domain, which contains a single TNFRassociated factor (TRAF) binding site40,46,47. The Fn14 receptor is able to
associate with four of the six TRAF proteins, TRAF1, TRAF2, TRAF3, and
TRAF5, at the predicted sequence motif44,48. These adaptor proteins lead to a
vast array of signaling capabilities mediated by the TWEAK-Fn14 signaling axis.

TWEAK-Fn14 system in myogenesis
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While TWEAK is constitutively and ubiquitously expressed in a number of
different cell types as a Type II transmembrane protein, the Fn14 receptor is
expressed at very low levels in healthy, mature tissue 49. However, in response to
injury and disease conditions, the expression of the Fn14 receptor is dramatically
increased and TWEAK undergoes furin-mediated cleavage to its secreted form. It
is also notable that in contrast to mature muscle fibers, satellite cells and primary
myoblasts constitutively express the Fn14 receptor50,51. Overall, the Fn14
receptor serves as the rate-limiting step in the TWEAK-Fn14 signaling axis49.
The TWEAK-Fn14 dyad has important roles in the regulation of skeletal
muscle mass. Previous studies from our laboratory have shown that TWEAK
induces myoblast proliferation but inhibits their differentiation into multinucleated
myotubes by reducing the stability of the MyoD protein and inhibiting the
expression of myogenin (Figure 1.1)51,52. This inhibitory effect of TWEAK on
myogenesis is mediated through the canonical arm of the NF-κB signaling
pathway as evidenced by improved myogenesis in cells overexpressing a
dominant negative mutant of IB kinase (IKK)β, but not IKKα52. Intriguingly,
recent studies have shown that TWEAK can also induce myoblast fusion. While
high levels of TWEAK (≥100 ng/ml) inhibit the differentiation of myoblasts into
myotubes, low levels of TWEAK (10 ng/ml) have been shown to facilitate fusion
of myoblasts leading to the formation of larger myotubes12. The pro-fusion role of
TWEAK at lower concentrations was shown to be mediated through activation of
the non-canonical NF-κB signaling cascade53.
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The commitment of satellite cells to undergo self-renewal or differentiate
into myogenic cells is characterized by expression of the proteins, Pax7 and
MyoD. Satellite cells are Pax7+/MyoD-, whereas differentiated myoblasts are
Pax7-/MyoD+. Ex vivo studies on myofiber explants have shown that low levels of
TWEAK (10 ng/ml) decrease the number of Pax7+/MyoD- satellite cells and
increase the proportion of Pax7-/MyoD+ myoblasts through repression of Notch
signaling and activation of NF-κB signaling54. With TWEAK inducing canonical
NF-κB signaling in one aspect of myogenesis and non-canonical NF-κB signaling
in another, it would seem that there is cross-talk between the two to facilitate
successful myogenesis.
The regenerative capacity of mature muscle is crucial for good health and
impairment in the regenerative process is a mainspring in the loss of skeletal
muscle in many diseases55,56. Intramuscular injection of cardiotoxin (CTX) is a
proven model for inducing satellite cell-driven muscle regeneration. The
expression of TWEAK and Fn14 are greatly increased 3-5 days post-CTX
injection in WT mice. TWEAK appears to negatively regulate skeletal muscle
regeneration in vivo. Skeletal muscle regeneration was significantly improved in
TWEAK-knockout (KO) mice compared to wild-type mice 57. The exact opposite
phenotype was observed in TWEAK-transgenic (Tg) mice which overexpress
TWEAK in skeletal muscle 57. In accordance with the data from myofiber
explants, the number of satellite cells was also significantly increased in the
regenerating myofibers of TWEAK-KO mice54. Additionally, TWEAK is known to
be a pro-inflammatory molecule, which in the context of higher concentrations or
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chronic disease states may perturb the normal immune response, leading to a
cytotoxic environment that is not conducive to regeneration 56,58. Collectively,
these findings suggest that elevated levels of TWEAK impair skeletal muscle
regeneration.

TWEAK and skeletal muscle metabolism
Skeletal muscle contains four different fiber types: I, IIA, IIX, IIB each expressing
a different myosin heavy chain (MyHC) isoform and having specific metabolic
qualities10,59-61. Skeletal muscle maintains the ability to transition from one fiber
type to another depending on the specific needs of the muscle as a whole 10,59,62
with MyHC type I fibers being considered “slow oxidative” and MyHC type II
fibers being considered “fast glycolytic.” The type I fibers are considered to have
a high mitochondrial content, prefer fatty acid oxidation, and exhibit a slower
contraction-relaxation profile. In contrast, type IIB fibers have less mitochondrial
content, prefer glycolytic metabolism, and exhibit a much faster contractionrelaxation profile. Along this spectrum, the MyHC type IIA and IIX fibers fall
somewhere in the middle, having intermediate properties10,59-61. Transition from
slow-to-fast type and vice-versa is an important component of skeletal muscle
plasticity 62.
TWEAK appears to promote fast-type fibers in skeletal muscle. One of the
key upstream regulators of skeletal muscle fiber composition, mitochondrial
content, and oxidative metabolism is peroxisome proliferator-activated receptor
gamma, coactivator 1 alpha (PGC-1α)63,64. In muscle-specific transgenic mice
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that overexpress PGC-1α, there is a much higher proportion of Type I and IIa
muscle fibers65. Our lab has found that TWEAK represses PGC-1α in skeletal
muscle66. In both extensor digitorum longus (EDL) and soleus muscles of
TWEAK-Tg mice, we found that there was a significant reduction in type I
myofibers with a concomitant increase in type II muscle fibers67. In stark contrast,
the skeletal muscle of TWEAK-KO mice showed an increase in the proportion of
type I fibers 67. Additionally, subsarcolemmal and intermyofibrillar mitochondrial
content was significantly increased in 5-month old TWEAK-KO mice, which was
accompanied by improved exercise capacity compared to wild-type mice 66. In
addition, the skeletal muscle of TWEAK-KO mice showed a significant increase
in the transcript levels of PGC-1α and several other molecules related to
oxidative metabolism 66. These results were supported by similar findings in
cultured myotubes treated with TWEAK 66 and also in cardiomyocytes through
the TWEAK-Fn14-TRAF2-canonical NF-κB pathway 68.
Skeletal muscle is responsible for a majority of glucose disposal in the
human body. Impairment in skeletal muscle glucose handling capacity leads to
glucose and insulin intolerance. Recent studies in our laboratory have shown that
with progressive age, skeletal muscle-specific TWEAK-Tg mice gain a
considerably higher amount of body weight and fat mass compared to littermate
control mice 69. These mice also demonstrate glucose intolerance and insulin
insensitivity. Increased levels of TWEAK inhibit AMPK and reduce the levels of
glucose transporter type 4 (GLUT4), a major glucose transporter in skeletal
muscle. Moreover, it was found that TWEAK represses the levels of Krüppel-like
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factor 15 (KLF15); myocyte enhancer factor 2 (MEF2), and PGC-1α, which are
essential for the activation of the GLUT4 locus 69. Collectively, these studies
show the broad reach that TWEAK has in the regulation of skeletal muscle
metabolic functions. Please refer to Figure 1.2 for a mechanistic summary and
Figure 1.3 for a summary of TWEAK’s physiological effects.

TWEAK-Fn14 system and skeletal muscle atrophy
Muscle wasting or atrophy is the result of a perturbation in proteostasis indicated
by accelerated degradation of muscle proteins relative to the synthesis of new
protein and is typically caused by reduced muscle tension in the case of disuse
conditions or pathophysiology in a myriad of diseases. As a whole, muscle
atrophy is characterized by a decrease in protein content, fiber diameter, force
production, and fatigue resistance2. The TWEAK/Fn14 signaling axis has been
shown to play a significant role in muscle atrophy through activation of the
ubiquitin-proteasome system (UPS), autophagy-lysosomal system (ALS), and
activation of caspases. However, blocking these downstream effector pathways
does not completely ameliorate the atrophy phenotype, indicating that other
mediators of skeletal muscle atrophy are at play.
One commonality among many catabolic conditions is the expression of
two E3 ubiquitin ligases, MuRF1 and MAFBx. These two ligases label, via
ubiquitination, specific target proteins for degradation by the 26S proteasome
and are thought to be the drivers of muscle proteolysis 70. Studies in our lab have
identified TWEAK as a potent muscle-wasting cytokine even at low levels (10
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ng/ml) causing significant atrophy and promoting the degradation of creatine
kinase and MyHC protein in cultured myotubes71. TWEAK activates NF-κB,
which has been shown to be responsible for the upregulation of MuRF1 and
targeted blocking of NF-κB significantly reduced the loss of MyHC and the
atrophy phenotype as a whole72-74. TWEAK also causes muscle wasting in vivo
where chronic administration of soluble TWEAK induced a significant reduction in
body weight, skeletal muscle mass, and fiber cross-sectional area71. In
generating muscle-specific TWEAK transgenic (Tg) mice, founders that
expressed extremely high mRNA levels of TWEAK (>16-fold increase) were
discovered to have severe muscle loss and neonatal lethality71. Nonetheless,
TWEAK-Tg mice expressing TWEAK mRNA at comparatively more moderate
levels (4 - 6-fold increase) exhibited muscular atrophy and interstitial fibrosis, but
without the neonatal lethality67. In support of the in vitro studies, TWEAK-Tg mice
were shown to have elevated activation of NF-κB, increased expression of
MuRF1, and ubiquitination of MyHC in skeletal muscle in naïve conditions

67,71.

In addition to the UPS, TWEAK has also been shown to elevate the expression
of several components of autophagy-lysosomal system (ALS) 75. In the ALS, a
portion of the cytoplasm is partitioned off by a double-membrane autophagosome
where ubiquitinated proteins, cellular debris, and organelles that may be too big
or are unsuitable for degradation by the proteasome are trapped. Subsequently,
the autophagosome fuses with the lysosome, where the contents of the vesicles
are degraded 76,77. It was discovered that several genes of the ALS were
upregulated in conjunction with formation of autophagosomes in the skeletal
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muscle of mice after denervation or a period of starvation indicating that the ALS
may play an important role in muscle atrophy 37,78. In support of this finding, our
lab has shown that several autophagy genes such as: Beclin1, LC3B, Atg5, and
Atg12 are significantly increased in response to TWEAK treatment in cultured
myotubes 75. Additionally, in studies of TWEAK-treated myotubes that blocked
NF-κB using adenoviral and shRNA techniques, the expression of Beclin1 was
significantly reduced suggesting that the TWEAK-Fn14-NF-κB axis is involved in
the activation of the ALS75.
The caspases, another important player in protein degradation, were also
found to be upregulated in response to TWEAK75. MuRF1 of the UPS can
ubiquitinate MyHC, but it cannot complete this task unless the proteins are
removed from the actomyosin complex. This would implicate other proteolytic
systems such as the caspase system in the process of muscle atrophy, which
has been demonstrated in catabolic conditions such as diabetes24. Activation of
caspase-3 was found to be imperative for this process and facilitated a 125%
increase in protein degradation by the UPS24. Furthermore, after tibial
denervation in caspase 3-KO mice, the gastrocnemius muscle weighed more and
displayed a larger myofiber cross-sectional area when compared to wild-type
mice79. Studies from our lab have shown that TWEAK causes an increase in
caspase-8 and caspase-3 mRNA levels in C2C12 myotubes after 24 hours of
treatment75. Caspase-8 is responsible for activating pro-caspase-3 to its
activated, cleaved form. Elevated cleaved caspase-3 was evidenced by western
blot analysis of C2C12 myotubes in response to treatment with TWEAK
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75.

Moreover, Z-VAD-FMK, a pan-caspase inhibitor, attenuated the degradation of
MyHC in TWEAK-treated myotubes 75. Collectively, these findings suggest that
caspases are involved in TWEAK-induced muscle atrophy. However, it remains
unknown whether the TWEAK-induced activation of caspases can also lead to
skeletal muscle cell death in vivo and in vitro.
Even though TWEAK is an inflammatory cytokine, it was notable to find
that TWEAK-Fn14 system mediates skeletal muscle atrophy in disuse conditions
and during starvation, which generally do not involve any overt inflammatory
response 67,80-82. Levels of Fn14, but not TWEAK, are increased in skeletal
muscle in disuse conditions such as denervation or immobilization. The role of
the TWEAK-Fn14 system in skeletal muscle atrophy was confirmed by the
findings that denervation- or starvation-induced loss of skeletal muscle mass is
inhibited in TWEAK-KO mice 67,80. Conversely, TWEAK-Tg mice showed
increased loss of skeletal muscle mass in response to denervation compared to
littermate control mice 67. Consistent with studies in cultured myotubes, TWEAKFn14 signaling increases NF-κB and expression of MuRF1 in denervated skeletal
muscle of mice 67.
Our recent studies have also demonstrated that TWEAK represses the
expression of PGC-1α in cultured primary myotubes and in denervated skeletal
muscle of mice 66,83. Overexpression of PGC-1α rescues TWEAK-induced
atrophy and activation of NF-B and the components of UPS in cultured
myotubes. Furthermore, progressive muscle atrophy in TWEAK-Tg mice is
significantly attenuated in TWEAK-PGC-1α double Tg mice suggesting that PGC-
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1α plays an important role in TWEAK-induced muscle atrophy 83. Furthermore,
our studies have provided evidence that there are reciprocal interactions
between TWEAK-Fn14 and PGC-1α in denervated muscle. While TWEAK-Fn14
signaling represses the expression of PGC-1α, transgenic overexpression of
PGC-1α inhibits the expression of Fn14 in denervated skeletal muscle of mice

83.

Please refer to Figure 1.2 for a mechanistic summary and Figure 1.3 for a
summary of TWEAK’s physiological effects.

Apoptosis
Apoptosis and necroptosis are two modes of “programmed” cell death which play
important roles during embryonic development, morphogenesis, ontogeny, and
proper functioning of the immune system through regulating cell turnover and
removal of harmful cells. Apoptosis involves cell membrane blebbing, volume
contraction, nuclear condensation, and endonucleolytic cleavage of DNA84. This
should not be confused with necrosis or necroptosis due to various differences
mechanistically and molecularly, but the most obvious is that apoptosis results in
the “orderly parceling” of cellular contents that are then phagocytosed and do not
initiate an inflammatory response85,86. Conversely, necroptosis is the “lesscontrolled” process where intrinsic factors poke holes in the cell membrane,
releasing cellular contents, and initiating a subsequent inflammatory response 87.
These two processes are independent, but can occur sequentially or
concomitantly87.
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Apoptosis relies on the downstream activation of catalytically inactive
cysteine proteases known as caspases. Activation of the caspases and initiation
of apoptosis can occur through intrinsic or extrinsic pathways. In the intrinsic
pathway, the state of the mitochondria determines whether or not the apoptotic
program is initiated. Normally, apoptosis is actively suppressed and maintained
until a negative stimulus such as the absence of growth factors or hormones,
reactive oxygen species (ROS), cytokines, and other insults upset the balance of
anti- and pro-apoptotic molecules87. The general paradigm consists of changes
to the inner mitochondrial membrane that result in the opening of the
mitochondrial permeability transition (MPT) pore, subsequent loss of
transmembrane potential, and release of pro-apoptotic proteins that are normally
sequestered in the intermembrane space87,88. Among these, there appears to be
a first wave of pro-apoptotic proteins followed by a second wave once the cell
has committed to an apoptotic fate.
The first wave consists of cytochrome c, Smac/DIABLO, and
HtrA2/Omi87,88. Collectively, the downstream signaling of these molecules leads
to the mitochondrial caspase-dependent pathway, requiring the formation of an
“apoptosome” and the degradation of inhibitors of apoptosis proteins (IAP). The
“apoptosome” is formed when cytochrome c binds to apoptotic protease
activating factor-1 (Apaf-1), which then leads to the binding of procaspase-9
resulting in its activation to caspase-987,88. However, Smac/DIABLO and
HtrA2/Omi need to be released to inhibit IAPs and promote a pro-apoptotic
milieu89,90. Activated caspase-9 cleaves procaspase-3 to the active caspase-3,
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which then executes the apoptotic program. In contrast to the first wave, the
second wave of proteins are responsible for chopping up the DNA and consists
of apoptosis inducing factor (AIF), endonuclease G, and CAD 87. The initiation of
mitochondrial release of pro-apoptotic proteins relies on the B-cell lymphoma
(Bcl-2) family.
The Bcl-2 family of 25 genes are subdivided into anti-apoptotic and proapoptotic proteins and are the factors responsible for the suppression or
commitment of the mitochondria to apoptosis through regulation of mitochondrial
membrane permeability. Some of the anti-apoptotic proteins include: Bcl-2, Bcl-x,
Bcl-XL, Bcl-XS, Bcl-w, BAG, and some of the pro-apoptotic proteins include: Bcl10, Bax, Bak, Bid, Bad, Bim, Bik, and Blk87. In general, the balance between
these two groups determines the fate of the cell with intrinsic stress promoting
the activation of the pro-apoptotic group91.
The extrinsic pathway typically relies on the binding of a protein ligand to a
transmembrane death receptor (DR) that initiates the pro-apoptotic cascade.
Members of the TNFRSF are among those that have been deemed DRs due to
the conserved death domain (DD) sequence on their cytoplasmic tail. The DRs
include: Fas, TNFR1, DR3, TNF-related apoptosis-inducing ligand (TRAIL)
(TRAIL-R1 or DR4, and TRAIL-R2 or DR5), and DR6. The receptor DD allows for
the recruitment of other protein molecules that have a DD of their own as well as
a death-effector domain at their N-terminus. An example of this is the wellcharacterized Fas-associated death domain (FADD) protein92,93. The deatheffector domain of FADD recruits procaspase-8 to the Fas-signaling complex,
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subsequently activating caspase-8, which then initiates the catalytic cleavage of
procaspase-3 to the active, cleaved caspase-3. Cleaved caspase-3 is the main
effector caspase in both apoptotic pathways and degrades many proteins leading
to the characteristic phenotype of apoptosis. One protein that cleaved caspase-3
targets is the inhibitor of caspase-activated deoxyribonuclease (ICAD), which is
bound in complex to CAD, an endogenous endonuclease, resulting in DNA
degradation and eventual cell death94,95.
Although skeletal muscle cells generally do not die during atrophy,
selective myonuclear apoptosis has been found to contribute to muscle wasting
in at least some atrophy conditions, such as aging and denervation 96-99.
Activation of some caspases can also induce protein degradation independent of
apoptosis as described above 34,100-102. Interestingly, the TNFRSF member Fn14
does not have a DD, but does have a TRAF binding domain on its cytoplasmic
tail that can bind TRAF240,46,47. TWEAK signaling through the Fn14 receptor is
known to activate both canonical and non-canonical NF-κB pathways and to
upregulate proteins of the UPS, the ALS, and the caspase system causing
severe muscle atrophy in response to TWEAK treatment53,54. Nakayama et al.
provided evidence that TWEAK-Fn14 signaling induced substantial levels of
caspase-3 and caspase-8 protein in immune cells showing that the TWEAK-Fn14
signaling axis had the ability to cause caspase-dependent apoptosis103.
Additionally, when TWEAK-treated cells were pre-treated with the pan-caspase
inhibitor Z-VAD-FMK, there was a significant increase in reactive oxygen
intermediates (ROI) and a subsequent shift to a necrotic phenotype103 indicating
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that TWEAK-Fn14 signaling can mediate multiple death pathways. In their
discussion, they likened the Fn14 receptor to TNFR2103. However, the signaling
mechanisms for the TWEAK-Fn14 upregulation of caspases and the role that
apoptosis may play in in TWEAK-induced loss of skeletal muscle mass remain
enigmatic.

Necroptosis
Another form of programmed cell death is necroptosis in which receptor
interacting protein (RIP) kinases play critical roles. The RIP kinases are a key
regulator at the heart of many cellular fate decisions with the ability to not only
signal cell-survival through activation of NF-κB, but also to signal cell death
through apoptosis and necroptosis104. RIPs are a family of seven
serine/threonine kinases with RIP1 being the most well studied member to date
in the context of DRs, such as Fas and TNFR1105. The differential signaling
pathways activated by RIP1 have been divided into the pro-survival complex I,
the apoptotic complex II, and the necroptotic complex IIB104. The membranebound complex I is formed in response to TNF signaling and results in RIP1
being recruited to TNFR1 by TRADD (TNFR1-associated death domain), which
acts as an assembly platform, recruiting TRAF2 as well104. Ultimately, this leads
to the activation of NF-κB and transcription of pro-survival genes such as cIAPs
and cFLIP (Cellular FLICE (FADD-like IL-1β-converting enzyme)-inhibitory
protein). Interestingly, the question that still remains is how does a protein switch
from having a pro-survival role to one that initiates cell death.
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It is thought that post-translational modifications to RIP1 and to other
members of complex I lead to the dissociation of complex I from TNFR1,
resulting in cytoplasmic localization. This is followed by recruitment of FADD and
the subsequent processing of procaspase-8 to activated caspase-8106. If prosurvival NF-κB signaling is successful, it is suggested that cIAP and cFLIP inhibit
apoptosis by preventing caspase-8 from executing caspase-3 mediated
apoptosis106-108. In the event of viral inhibition of the caspase system, the
necrosome is formed, serving as an additional layer of redundancy ensuring that
the cell death process is successful.
The necrosome in complex IIB is formed by the association of FADD,
RIP1, and RIP3. Unlike its role in complex I and II, the kinase activity of RIP1 is
required for the execution of necroptosis109. Furthermore, RIP1-RIP3
transphosphorylation is also necessary for necroptosis to proceed 110. Following
activation, the pseudokinase mixed-lineage kinase domain-like protein (MLKL) is
phosphorylated by RIP3, which effectively activates the necrosome111. MLKL
targets phosphatidylinositol phosphates (PIPs), cardiolipin (CL) and
phosphatidylglycerol (PG) and subsequently punches holes in the cellular
membranes leading to membrane rupture and organelle swelling, the hallmark
morphological characteristics of necroptosis111.

Regulation of Redox Homeostasis
Reactive oxygen species (ROS) have been associated with a diverse array of
signaling functions in both physiological and pathophysiological states. The
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production of ROS is a normal part of cellular metabolism with some tissues
being more metabolically active than others. When the production of ROS
exceeds the cell’s ability to process and defend itself from the cytotoxic effects of
ROS, this leads to a state of oxidative stress that can result in tissue injury.
Oxidative stress has been associated with many chronic disease states including
diabetes mellitus112, Alzheimer’s disease, amyotrophic lateral sclerosis (ALS),
and Duchenne muscular dystrophy113 to name just a few.
ROS consist of oxygen-centric chemicals whose properties make them
particularly prone to reacting with and changing the chemical nature of otherwise
stable molecules. This group consists of the superoxide radical (O2•-), the highly
reactive hydroxyl radical (•OH), and hydrogen peroxide (H2O2). Superoxide
radicals are generated in several different locations within the cell including the
mitochondria by the electron transport chain, the cellular membranes by NADPH
oxidase (NOX) enzymes, the cytosol by enzymes such as xanthine oxidase (XO),
and even extracellularly by phagocytes in response to injury and
inflammation112,114,115. Along the continuum of reactivity, superoxide is relatively
stable and can act as a weak oxidizing agent, but more importantly it is a source
for the production of hydroxyl radicals and hydrogen peroxide 112. Superoxide
radicals are able to produce these by liberating iron from iron-containing proteins
(ferritin116, hemoglobin, myoglobin) for the Fenton reaction, creating the volatile
hydroxide radical114,115.
O2•- + Fe(III) → Fe(II) + O2

and then, Fe(II) + H2O2 → •OH + OH- + Fe(III)
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Another reaction that superoxide radicals partake in is with the nitric oxide radical
(NO•) creating the powerful oxidant peroxynitrite (ONO2-)115. On the other hand,
hydrogen peroxide is a stable molecule with the ability to readily diffuse across
membranes and to act as a signaling molecule; whereas, hydroxyl radicals have
a very short half-life, react instantaneously and indiscriminately with most
biological molecules, and result in the propagation of toxic free radical chain
reactions112,114. ROS act as signal transducers regulating diverse downstream
signaling pathways in addition to their role in the oxidation of macromolecules
resulting in cytotoxicity.
The reason that ROS have received so much attention over the years is
due to their ability to cause oxidative damage to macromolecules. Lipid
peroxidation and the oxidation of DNA have received the most attention, but the
oxidation of enzymes through the addition of carbonyl groups can wreak havoc
on proteins as well112,114. In the process of lipid peroxidation, reactive free
radicals such as the hydroxyl radical can abstract a hydrogen from the methylene
(-CH2-) group of a fatty acid creating a carbon radical (-•CH-) that rearranges
itself to a diene and then binds to molecular oxygen to form a peroxyl
radical112,114. Ultimately, the peroxyl radical reacts with other lipids resulting in a
chain reaction that can change the overall membrane properties of the organelle
or cell. In addition, hydroxyl radicals can attack the deoxyribose sugar as well as
the purine and pyrimidine bases of DNA leading to single/double-strand breaks
and protein-DNA crosslinks112,114. Collectively, if oxidative stress is pervasive
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enough and the cell is unable to repair the damage, apoptosis or necrosis is
initiated. So, how do cells protect themselves from oxidative damage?
Cells maintain a number of antioxidant defense systems that reduce ROS
to non-reactive intermediates, thereby limiting their capacity to cause oxidative
damage. The most famous of these is the three-member family of superoxide
dismutase (SOD) enzymes, each of which have a specific subcellular localization
and each house specific metal cations capable of dismutating superoxide into
molecular oxygen and hydrogen peroxide. SOD1 (Cu-Zn-SOD) is localized to the
cytosol and mitochondrial intermembrane space, while SOD2 (Mn-SOD) is
localized to the mitochondrial matrix117,118. SOD3 or extracellular SOD also
contains Cu and Zn, but is localized to the extracellular milieu 117. The importance
of these SOD enzymes is highlighted by the association of mutations in SOD1
with familial ALS and lethal cardiomyopathy induced by knocking out SOD2 in
mice117. After dismutation, hydrogen peroxide can be converted to water and
molecular oxygen by catalase, which is localized to peroxisomes in close
proximity to the mitochondria114. A similar function is achieved by the glutathione
peroxidase (GPx), peroxiredoxin (Prx), and thioredoxin (Trx) enzymes that
function as reducing agents. These are just a few of the more well-known
antioxidant enzymes, with others being upregulated by the transcription factors
Nrf-2 and Ref-1119. Nrf-2 is activated by the disassociation of the KEAP1 protein
in response to excessive ROS, acting as a redox sensor. This frees up Nrf-2 to
bind to antioxidant response element (ARE) promoters on DNA leading to
transcription of additional antioxidant enzymes.
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Oxidative Stress in Skeletal Muscle
With skeletal muscle being the largest and one of the most metabolically active
tissues, it is imperative that the production of ROS be counterbalanced by
antioxidant defenses to maintain cellular homeostasis. Initially, ROS were
thought to be mediators of disease and high hopes were placed on treating these
diseases with high doses of exogenous antioxidants. With mixed results, further
research over the years has shown the importance of ROS and redox signaling
in normal physiology. Paradoxically, skeletal muscle fibers produce ROS in
response to exercise training120,121, which makes intuitive sense, but also
produce ROS in response to long periods of disuse122,123. This places ROS
production and possibly oxidative stress at the heart of anabolic adaptive
responses and catabolic atrophic responses in skeletal muscle.
The sources of ROS in skeletal muscle are the mitochondria, xanthine
oxidase (XO), and NADPH oxidases (NOXs), with NOX2 and NOX4 being the
homologues expressed in muscle. The multi-component NOX2 complex is found
in the transverse tubule membrane, sarcoplasmic reticulum, and sarcolemma
with evidence showing NOX2 as one of the major sources of ROS under resting
and contracting conditions124-127. During exercise training, there is an increase in
cytosolic ROS production with a subsequent increase in the antioxidant
enzymes, SOD2, GPx, and catalase127. By inhibiting NOX2, there is a reduction
in the adaptive gene expression that is typically upregulated in response to
endurance exercise and is thought to be due to the ROS-dependent regulation of
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calcium-controlled signaling cascades128. Additionally, mitochondrial biogenesis
is a well-known adaptive response that occurs in response to exercise training
through the upregulation of the transcription factor PGC1-α. ROS have been
shown to upregulate PGC1-α129, while dietary antioxidants have been shown to
block exercise-induced mitochondrial biogenesis. This suggests that ROS are
important for mitochondrial adaptation to exercise130. Insulin-dependent glucose
uptake124,131 and the translocation of GLUT4131 are two other areas where ROS
have been shown to be play a major role in muscle homeostasis. Collectively,
these suggest that ROS are essential for normal muscle physiology. However,
when the production of ROS exceeds the ability of the muscle to ameliorate their
toxic effects, this can lead to negative consequences.
Some of these negative consequences in response to excess ROS can
amount to nothing more than the fatigue that one feels after strenuous
exercise132 or can greatly accelerate the degradation of one’s quality of life in the
case of Duchenne muscular dystrophy124. Redox disturbances can play a primary
role in disease such as in the inherited defect to reductase selenoprotein N
(SEPN1) that leads to chronic oxidative stress in SEPN1-related myopathy133 or
a secondary role as in the case of Duchenne muscular dystrophy124. Under
catabolic conditions like these, cytokines are one of the major mediators of
muscle atrophy. TNF-α is known to cause an increase in ROS production and
initiates oxidative stress in the process of cell death134. A recent study on
macrophages found that TWEAK/Fn14 signaling results in an increase in ROS
produced in a NOX2 dependent manner,135 which is one of the major producers
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of ROS in skeletal muscle. Furthermore, previous analysis of microarray data
from our lab suggests that one of the pathways affected by TWEAK in myotubes
is that of oxidative stress136. Despite this, the relationship between TWEAK and
oxidative stress remains poorly understood and has not been investigated in
skeletal muscle.

Purpose and Hypothesis
Despite the quantum leap in our understanding of the TWEAK-Fn14 signaling
axis and the downstream effector pathways, there are still many questions that
need to be addressed. Of these, it remains unknown whether TWEAK can induce
cell death through apoptosis or necroptosis. It is notable that TWEAK mediates
skeletal muscle wasting in response to denervation and during aging, a condition
which also involves loss of neuromuscular junctions. There are reports
suggesting that selective myonuclear apoptosis occurs in these conditions
leading to a net loss of skeletal muscle mass. Furthermore, oxidative stress has
been implicated in skeletal muscle weakness and atrophy. However, it remains
unknown whether TWEAK can induce apoptosis and oxidative stress in skeletal
muscle. I hypothesize that the TWEAK/Fn14 axis signals cell death in an
alternative extrinsic apoptotic pathway similar to TNFR2 and that TWEAK
induces oxidative stress providing an additional mechanistic component that
enhances the accelerated protein degradation in skeletal muscle in catabolic
conditions.
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Figure 1.1: TWEAK’s effect on myogenesis. Satellite cells undergo myogenic
commitment, producing myoblasts. TWEAK inhibits the self-renewal of satellite
cells in favor of myogenic commitment and proliferation of myoblasts. At higher
concentrations, TWEAK inhibits the differentiation of myoblasts. Low
concentrations of TWEAK promote fusion of myocytes into myotubes; whereas,
high concentrations of TWEAK inhibit this process. In response to chronic
disease, TWEAK abates myofiber regeneration. Transcription factors expressed
at each stage of myogenesis are listed in red font.
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Figure 1.2: Schematic illustration of TWEAK and downstream signaling
cascades. The Fn14 receptor is upregulated on skeletal muscle in response to
injury or in disuse conditions, providing substrate for trimeric TWEAK to bind.
This leads to the recruitment of various TRAFs and cIAPs that lead to a myriad of
downstream signaling cascades. TWEAK inhibits PGC-1α, resulting in a
decrease in mitochondrial biogenesis. TWEAK elevates the expression of various
components of the autophagy lysosomal system (ALS) and promotes the
activation of the ubiquitin proteasome system (UPS) by stimulating the NF-κB
pathway and inhibiting Akt signaling. Inhibition of Akt also results in the activation
of the Foxo family of transcription factors, leading to proteosomal degradation of
28

muscle proteins through increased expression of MAFBx and MuRF1. In
addition, the TWEAK-Fn14 system activates the MAPK signaling cascades
resulting in the binding of AP-1 transcription factor to DNA and the expression of
genes such as: cytokines, chemokines and MMPs which contribute to collagen
remodeling and fibrosis. TRAF, TNF-receptor associated factor; cIAP, cellular
inhibitor of apoptosis; AP1, activator protein-1; FOXO, Forkhead box O.
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Figure 1.3: Physiological Effects of TWEAK. TWEAK-Fn14 signaling results in
a number of physiologically relevant consequences from muscle proteolysis and
atrophy to oxidative stress and inflammation in different conditions.
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CHAPTER 2: MATERIALS AND METHODS
Mice
Mice (strain: C57BL6) were purchased from Jackson Laboratory (Bar
Harbor, ME, USA). TWEAK-KO mice were provided by A. Ashkenazi137. The
genotype was confirmed by PCR utilizing tail DNA. Mice were housed and fed in
stainless steel cages on a 12 hour on and 12 hour off lighting schedule.
Sciatic denervation was performed by anesthetizing the mice with an
intraperitoneal injection of 2,2,2 tribromoethanol (Aldrich T4, 840.2 or equivalent)
at a concentration of 0.2ml/10 grams of body weight. Anesthesia was confirmed
with lack of response to a toe pinch. The mouse hindlimbs were shaved and an
~0.5cm incision was made proximal to the pelvis and the medial side of the right
leg. The muscles were separated with forceps and the sciatic nerve was lifted out
with a surgical hook. A 2-3mm section of the sciatic nerve was removed and the
incision was closed using surgical sutures. A sham denervation was performed
on the contralateral leg with an ~0.5mm incision followed by separation of
muscles. The incision was then closed utilizing surgical sutures. The mice were
allowed to recover for three days in their respective cages. On the third day, the
mice were euthanized by cervical dislocation and the tibialis anterior,
gastrocnemius, and soleus muscle were removed for subsequent analysis. All
experimental protocols with mice were in accordance with approved ethical
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guidelines of the Institutional Animal Care and Use Committee at the University
of Louisville.

Mouse Primary Myoblast Isolation
C57BL6 mice were euthanized and the hind limb muscles were isolated.
Excess connective tissues and fat were cleaned in sterile PBS followed by
mincing into coarse slurry and enzymatically digested at 37 °C for 1 h by adding
400 IU/ ml collagenase II (Worthington). The digested slurry was then spun,
pelleted and triturated several times and passed through a 70-μm and then 30μm cell strainer (BD Falcon). The filtrate was spun at 1,000g and suspended in
myoblast growth medium (Ham's F-10 medium with 20% FBS supplemented with
10 ng/ml of basic fibroblast growth factor). Cells were first refed after 3 days of
initial plating. For the first few passages, cells were also enriched by pre-plating
for removal of fibroblasts and selection of a pure myoblast population.

Cell Culture
Purified mouse primary myoblasts were plated in myoblast growth medium
consisting of Ham's F-10 Nutrient Mix supplemented with 20% FBS, 1%
Penicillin-Streptomycin (Gibco), and 10 ng/ml of basic fibroblast growth factor
(Peprotech). Upon reaching a cellular confluence of ~85-90%, the growth
medium was replaced with differentiation medium consisting of Dulbecco's
Modified Eagle's Medium (ATCC) supplemented with 2% horse serum (Gibco)
and 1% Penicillin-Streptomycin (Gibco). The cells were allowed to fully
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differentiate for 72 hours with replenishment of differentiation medium every 48
hours.

RNA Isolation and quantitative real-time PCR
RNA was isolated from cultured myotubes or mouse skeletal muscle using
the RNeasy Mini Kit (Qiagen). The RNA in each sample was measured using the
NanoDrop instrumentation (NanoDrop Technologies). To synthesize cDNA, 1µg
of purified RNA was utilized in conjunction with the High-Capacity cDNA Reverse
Transcription Kit (Applied Biosystems). Primers for qRT-PCR were designed
using Vector NTI Xi software (Invitrogen). The sequences for all primers can be
found in Table 1.
Table 1. Sequence of the primers used for QRT-PCR assay.
Gene
name

Forward Sequence

Reverse Sequence

SOD1
SOD2
SOD3
GPx1
GPx3
CAT

5’-TGAACCAGTTGTGTTGTCAG-3’
5’-TGGCTTGGCTTCAATAAGGA-3’
5’-AGGTGGATGCTGCCGAGAT-3’
5’-GGGCTCCCTGCGGGGCAAGGT-3’
5’-TCTCAAGTATGTTCGACCAGGTGG-3’
5’-CGCCACATGAATGGCTATGGATC-3’

5’-TCCATCACTGGTCACTAGCC-3’
5’-AAGGTAGTAAGCGTGCTCCCACAC-3’
5’-TCCAGACTGAAATAGGCCTCAAG-3’
5’-ATGTACTTGGGGTCGGTCATG-3’
5’-TCCCCGTTCACATCTCCTTT-3’
5’-AAGCCTTCCTGCCTCTCCAACA-3’

XDH
NOX2
β-actin

5’-ATCTGGAGACCCACTGCACC-3’
5’-AGTGTGTCGAAATCTGCTCTCCTT-3’
5’-CAGGCATTGCTGACAGGATG-3’

5’-TGTGCTCACGAAGAGCTCCAT-3’
5’-TACTCTTCGTTCTCATTGTCACCG-3’
5’-TGCTGATCCACATCTGCTGG-3’

Quantification of mRNA was done using the SYBR Green method on ABI Prism
7300 Sequence Detection System (Applied Biosystems). The thermal conditions
consisted of an initial denaturation at 95 °C for 10 min followed by 40 cycles of
denaturation at 95 °C for 15 s, annealing and extension at 60 °C for 1 minute and
a final step melting curve of 95 °C for 15 s, 60 °C for 15 s and 95 °C for 15 s. All
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reactions were carried out in duplicate to reduce variation. The results were
exported to Microsoft Excel for further analysis. Data normalization was
accomplished using the endogenous control β-actin and the normalized values
were subjected to a 2−ΔΔCt formula to calculate the fold change between the
control and experimental groups.

Western Blot
Quantitative estimation of various proteins was done by performing a western
blot. Cultured myotubes were trypsinized followed by centrifugation at 3500 rpm.
The pellet was washed with PBS and lysed in lysis buffer (50 mM Tris-Cl (pH
8.0), 200 mM NaCl, 50 mM NaF, 1 mM dithiotheritol, 1 mM sodium
orthovanadate, 0.3% IGEPAL and protease inhibitors). Approximately, 100 μg of
protein was resolved on each lane on 10% SDS–polyacrylamide gel
electrophoresis, electrotransferred onto nitrocellulose membrane, and probed
using specific antibodies and detected by chemiluminescence (Bio-Rad).
Approximate molecular masses were determined by comparison with the
migration of pre-stained protein standards (Bio-Rad).

Flow Cytometry
Apoptosis was assessed by Annexin V/PI staining followed by FACS
according to the manufacturer’s instructions (BD Biosciences). In brief, myotubes
were collected and washed with PBS and then resuspended in 1X binding buffer.
100 μl containing ~ 1 x 105 cells were then transferred to test tubes. As control
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groups, there were unstained cells, cells stained with Annexin V alone, and cells
stained with PI alone in addition to the experimental groups incubated in both
stains. The tubes were incubated at room temperature in the dark for 15 mins.
Subsequent FACS analysis was performed on a C6 Accuri cytometer (BD
Biosciences) equipped with two lasers.

Lactate Dehydrogenase (LDH) Assay
The amount of LDH in culture supernatants was measured using an LDH
Cytotoxicity Assay kit following the protocol suggested by the manufacturer
(Thermo Scientific).

Oxidative Stress Probe
For the detection of oxidative stress, TWEAK-treated myotubes were
incubated with CellROX deep red reagent (Life Technologies) according to
manufacturer instructions with minor modification to the incubation period for 45
mins at 37° C rather than the 30 mins. Cultured myotubes were then
counterstained with Hoechst 33342 (Life Technologies) and visualized with a
Nikon Eclipse TE 2000-U microscope (Nikon). Equivalent contrast adjustments
were made using ImageJ software.

Statistical Analysis
All experimental protocols with mice were in accordance with approved
ethical guidelines of the Institutional Animal Care and Use Committee at the

35

University of Louisville. Statistical analyses used two-tailed Student’s t-test to
compare quantitative data populations with normal distribution and equal
variance. A value of P<0.05 was considered statistically significant unless
otherwise specified.
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CHAPTER 3: RESULTS

The major goal of my project was to investigate whether TWEAK induces skeletal
muscle death and whether oxidative stress plays a role in TWEAK-induced
cytotoxicity.

TWEAK induces cytotoxicity in mouse primary myotube cultures. TWEAK
has been shown to induce muscle atrophy both in vivo and in vitro 66,67,71,75,82,138140.

We investigated whether TWEAK also affects the survival of cultured

myotubes. We first established primary myoblast cultures from C57BL6 mice. At
90% confluency, the medium of the cells was changed to differentiation medium,
(DM) which led to the formation of multinucleated myotubes by 72h. The
myotube cultures were then treated with increasing amounts of soluble TWEAK
protein. As shown in Figure 3.1A, the number of myotubes were significantly
reduced in TWEAK-treated cultures compared to controls.
Lactate dehydrogenase (LDH), is a soluble yet stable enzyme found inside
every living cell. When the cell membranes are compromised or damaged in any
way, LDH is released into the surrounding extracellular space. The presence of
LDH in the culture medium is routinely used as a cell death marker and the
relative amounts of live and dead cells within the medium can be quantitated by
measuring the amount of released LDH using a colorimetric or fluorometric
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assay. To quantify TWEAK cytotoxicity on myotubes, we treated primary
myotube cultures with soluble 10 or 100 ng/ml TWEAK protein and the amounts
of LDH in culture supernatants was measured at 24, 48, 72 and 96h. There was
no significant difference in the amounts of LDH in culture supernatants at 24h
after addition of TWEAK. However, the amounts of LDH were significantly
increased in TWEAK-treated cultures compared to controls after 48h of
treatment. Moreover, the amounts of LDH in culture supernatants was
significantly higher in cultures treated with 100 ng/ml of TWEAK compared to 10
ng/ml indicating a dose-dependent effect of TWEAK on myotube viability (Figure
3.1B). These results suggest that TWEAK diminishes the survival of primary
myotubes in cultures.

TWEAK induces apoptosis in myotube cultures. Cell death can occur through
apoptosis87 or necrosis141,142. Thusly, we next investigated whether TWEAK
induces apoptosis in cultured myotubes. Primary myotubes were treated with 100
ng/ml TWEAK for 48h and both floating and adherent myotubes were collected.
The cells were incubated with propidium iodide (PI) dye, which is membrane
impermeant and only binds to DNA once the cell membrane has been
compromised. The cells were also incubated with antibody against Annexin V, a
marker for apoptosis through binding to phosphatidylserine, which is normally
localized to the inner leaflet of the plasma membrane. The cells were analyzed
by performing FACS. Intriguingly, treatment of cells with TWEAK increased both
early and late apoptosis in cultured myotubes (Figure 3.2A). Quantification of
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Annexin V+ and PI+ cells further confirmed that TWEAK increased both early and
late apoptosis in cultured myotubes (Figure 3.2B).

TWEAK increases the levels of various biochemical markers of apoptosis
in cultured myotubes. Apoptosis is a highly coordinated process which involves
the activation of a number of caspases, ultimately culminating in cell death143.
Many of the caspases undergo proteolytic cleavage leading to their activation 24.
Using Western blot, we measured the levels of various caspases. As shown in
Figure 3, treatment with TWEAK significantly increased the levels of cleaved
isoforms of capsase-3 and caspase-9 in myotubes (Figure 3.3).
Poly (ADP-ribose) polymerase (PARP) is an important protein which is
involved in DNA repair in response to a variety of environmental stresses. PARP
is one of the main cleavage targets of caspase-3 both in vitro and in vivo144.
Cleavage of PARP facilitates cellular disassembly and serves as a marker of
cells undergoing apoptosis145. Our immunoblotting analysis showed that TWEAK
drastically increases the levels PARP in cultured myotubes within 24h, further
confirming that treatment of TWEAK induces apoptosis of myotubes (Figure 3.3).
Apoptosis-inducing factor (AIF) is a ubiquitously expressed flavoprotein
that plays a critical role in the intrinsic apoptotic pathway. AIF is normally
localized to the mitochondrial intermembrane space and released in response to
apoptotic stimuli88. Moreover, Bax is a key component for apoptosis induced
through mitochondrial stress as well. Upon apoptotic stimulation, Bax forms
oligomers and translocates from the cytosol to the mitochondrial membrane85.
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Through interactions with pore proteins on the mitochondrial membrane, Bax
increases the membrane's permeability, which leads to the release of
cytochrome c from mitochondria, activation of caspase-9, and initiation of the
caspase activation pathway for apoptosis85. We measured the levels of AIF and
Bax in control and TWEAK-treated myotube cultures by performing western blot
(Figure 3.3). Our results showed that TWEAK slightly increases the levels of both
AIF and Bax proteins in myotubes. These results indicate that both the intrinsic
and extrinsic pathways may be involved in the induction of apoptosis in response
to TWEAK.

Z-VAD-FMK, a pan-caspase inhibitor reduces the TWEAK-induced
cytotoxicity in myotube cultures. We next investigated whether apoptosis is a
mechanism of TWEAK-induced cell death. We used z-VAD-FMK, a cell
permeable peptide which effectively reduces the activation of various
caspases103. Myotube cultures were incubated with vehicle alone (i.e. DMSO) or
20 µM z-VAD-FMK peptide. After 2h, the cells were treated with 10 or 100 ng/ml
TWEAK for 48 or 72h. As shown in Figure 3.4A, treatment with z-VAD-FMK
peptide considerably improved the survival of myotubes in TWEAK-treated
cultures. Moreover, the amounts of LDH in culture supernatants was significantly
reduced in TWEAK-treated cultures incubated with z-VAD-FMK (Figure 3.4B).
These results suggest that apoptosis contributes to myotube mortality in
response to TWEAK.
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TWEAK induces necroptosis in cultured myotubes. Apoptosis has been
traditionally considered as the physiological mode of cell death. However,
necroptosis, which is morphologically related to necrosis, is now recognized as
another mode of programmed cell death141,146. RIP1 kinase is activated through
oligomerization of upstream adaptor molecules such as FADD and TNF receptorassociated death domain (TRADD) that are triggered by TNFα or Fas ligand147.
Subsequently, activated RIP1 activates RIP3 resulting in necroptosis. We next
investigated whether TWEAK induces the markers of necroptosis in myotubes.
As shown in Figure 3.5A, treatment of cells with TWEAK increased the levels of
RIP1 and RIP3, although there are some nonspecific bands, in cultured
myotubes suggesting that necroptosis may also contribute to cell death in
response to TWEAK treatment. Recently, a peptide inhibitor of necroptosis
known as necrostatin-1 (Nec-1) was developed which inhibits the activity of
RIP1148. To understand whether necroptosis is a mechanism of TWEAK-induced
myotube cell death, we employed Nec-1. We found that pretreatment with Nec-1
did not considerably reduce the TWEAK-induced cell death in myotube cultures
(Figure 3.5B). Interestingly, the LDH assay showed that pretreatment with Nec-1
significantly reduced the amount of LDH (Figure 3.5C). Further studies are
required to elucidate the role of RIP1 in TWEAK-induced cell death. Collectively,
these results suggest that TWEAK induces both necroptosis and apoptosis in
cultured primary myotubes; however,
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TWEAK induces oxidative stress in cultured myotubes. While TWEAK
receptor Fn14 contains TRAF binding domains, it lacks the death receptor
domain. Recent studies have suggested that oxidative stress is one of the
important stimuli which can lead to cell death through both apoptosis and
necroptosis134. Previous studies have shown that proinflammatory cytokines such
as TNF-α induce oxidative stress in cultured myotubes149,150. We next sought to
investigate whether TWEAK can induce oxidative stress in myotubes. For
measuring oxidative stress, we used the CellROX Deep Red reagent, a cellpermeant, fixable fluorogenic probe of ROS. The CellROX probe reacts with
ROS such as: superoxide anion, hydroxyl radical, peroxynitrite, and to a lesser
extent, nitric oxide (Invitrogen communication). By competing with endogenous
antioxidants, CellROX functions as a marker of excessive ROS and therefore,
oxidative stress. Primary myogenic cultures were treated with 10 or 100 ng/ml of
TWEAK for 24 h after which the cells were incubated with the CellROX probe
followed by counterstaining with Hoechst. A fluorescence microscope was used
to capture pictures of the myotubes. In the group treated with 10 ng/ml of
TWEAK, there wasn’t a significant increase in the levels of oxidative stress.
However, the amount of oxidative stress in myotubes was drastically increased
upon treatment with 100 ng/ml of TWEAK (Figure 3.6). These results indicate
that TWEAK induces oxidative stress in cultured myotubes.

TWEAK perturbs the expression of various pro-oxidant and antioxidant
molecules in cultured myotubes. Redox homeostasis is maintained by a
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delicate balance between the production of potentially cytotoxic ROS and the
cellular production of antioxidant molecules119. We next investigated whether
TWEAK affects the expression of genes whose products are involved in the
regulation of redox balance. Primary myotubes were treated with vehicle alone or
100 ng/ml of TWEAK for 48h. The cells were analyzed by performing quantitative
real-time PCR (QRT-PCR) assay. As shown in Figure 3.7, TWEAK drastically
reduced the levels of several antioxidant molecules including SOD2 and SOD3,
GPx1 and, CAT in myotubes. By contrast, the mRNA levels of xanthine
oxidoreductase (XDH), a pro-oxidant molecule, were significantly upregulated in
TWEAK-treated cultures (Figure 3.7). Additionally, the expression of another prooxidant molecule, NOX2, was elevated. These results suggest that TWEAK
induces oxidative stress by perturbing the expression of pro-oxidant and
antioxidant molecules.

N-acetyl Cysteine (NAC) reduces cell death in TWEAK-treated primary
myotube cultures. N-acetyl cysteine (NAC), a general antioxidant, has been
shown to reduce levels of ROS and carbonylated proteins in skeletal muscle in
many disease models 151-153. We investigated whether NAC can prevent cell
death in TWEAK-treated myotube cultures. Primary myotubes were incubated
with vehicle alone, 0.1, or 0.5mM NAC for 2h followed by treatment with 100
ng/ml of TWEAK for 72h. The amount of LDH produced in culture supernatants
was measured using a colorimetric assay. Treatment of myotubes with NAC
alone had no effect on the survival of myotubes. Moreover, there was no
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significant difference in the levels of TWEAK-induced cytotoxicity in myotube
cultures treated with vehicle alone or 0.1mM NAC. Interestingly, we found that
TWEAK-induced cytotoxicity was significantly reduced in the presence of 0.5mM
NAC (Figure 3.8). These results provide initial evidence that TWEAK may induce
myotube mortality through disrupting redox balance.

TWEAK perturbs oxidative stress in skeletal muscle during denervation.
We have previously reported that TWEAK-Fn14 system is a major mediator of
denervation-induced skeletal muscle atrophy 67,154. We investigated whether
TWEAK affects the expression of specific genes which are involved in redox
homeostasis. The hind limb muscle of 2 month old wild-type and TWEAK-KO
mice were denervated by transection of sciatic nerve and 3 days later, the
gastrocnemius muscle was isolated. By performing QRT-PCR assay, we first
investigated how the expression of various oxidant and anti-oxidant molecules
are affected by denervation. Results showed that the mRNA levels of SOD1,
SOD3, GPx1, GPx2, XDH, and NOX2 were increased whereas the levels of
SOD2 are reduced in WT denervated muscle compared to corresponding WT
undenervated controls (Figure 3.9A). We also compared the mRNA levels of
these molecules in undenervated and denervated skeletal muscle of TWEAK-KO
mice. Interestingly, we did not observe any increase in the mRNA levels of most
of these oxidant and anti-oxidant genes (Figure 3.9B). While statistical
significance could not be achieved due to a small number of mice in each group
(N=3), these results provide initial evidence that oxidative stress is increased in
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skeletal muscle upon denervation and TWEAK may be a major player in such
induction. We are planning to perform additional experiments where a larger
cohort of mice will be used and QRT-PCR analysis will be performed at different
time points after denervation.
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FIGURE 3.1. TWEAK induces cytotoxicity in mouse primary myotube
cultures. (A) Mouse primary myotubes were treated with 10 ng/ml or 100 ng/ml
of TWEAK for 72 h. Representative images presented here demonstrate that
myotube atrophy and cell death were increased in a dose-dependent manner.
(B) Mouse primary myotubes were treated with 10 ng/ml or 100 ng/ml of TWEAK
for a total of 96 h. An LDH assay was performed on cell culture supernatant at
each time point. TWEAK causes a progressive dose-dependent increase in
cytotoxicity. N=3 at each time point. *p<0.05, values significantly different from
vehicle-treated controls at indicated time points. #p<0.05, values significantly
different from cultures treated with 10ng/ml TWEAK.
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FIGURE 3.2. TWEAK induces apoptosis in myotube cultures. Myotubes were
treated with vehicle alone or 100 ng/ml of soluble TWEAK protein for 48 h. The
cells were collected, stained with PI and Annexin V and subjected to FACS
analysis. (A) Representative dot plots of control and TWEAK-treated mouse
primary myotubes. (B) Quantification of early and late apoptosis in control and
TWEAK-treated myotube cultures assayed by the FACS method. Results
demonstrate that TWEAK increases both early and late apoptosis as
characterized by Annexin V vs. PI intensity. N=3 in each group. *p<0.05, values
significantly different from control cultures.
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FIGURE 3.3. TWEAK increases the levels of biochemical markers of
apoptosis in cultured myotubes. Myotubes were treated with 100ng/ml
TWEAK protein for different time points ranging from 0 to 48h. Protein extracts
made were analyzed for the levels of various proteins involved in apoptosis.
Immunoblots presented from two independent sets of experiments show that
TWEAK increases the levels of cleaved PARP, cleaved caspase-3, and -9, AIF,
and Bax in cultured myotubes.
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FIGURE 3.4. Inhibition of caspases reduces TWEAK-induced cytotoxicity in
myotube cultures. (A) Fully differentiated myotubes were pre-incubated with
20µM Z-VAD-FMK, a pan-caspase inhibitor, for 2h followed by treatment with the
indicated amount of TWEAK for 48h. Bright-field images were taken and
representative images suggest that treatment with Z-VAD-FMK considerably
reduced the TWEAK-induced myotube cell death. Scale bar (black): 50µM. (B)
An LDH assay was performed to quantify the cytotoxicity with respect to the pancaspase inhibitor, Z-VAD-FMK. At 72h after TWEAK treatment, there is a drastic
increase in cytotoxicity in the groups treated with 100 ng/ml of TWEAK.
Treatment with Z-VAD-FMK significantly decreased the cytotoxicity in TWEAKtreated myotubes. N=3 in each group. *p<0.05, values significantly different from
control cultures. #p<0.05, values significantly different from TWEAK-treated
cultures incubated without Z-VAD-FMK peptide.
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FIGURE 3.5. TWEAK induces necroptosis in cultured myotubes. (A) Primary
myotubes were treated with 100 ng/ml TWEAK protein for indicated time period
and the levels of RIP1 and RIP3 protein were assayed by performing western
blot. Representative immunoblots presented here demonstrate that TWEAK
increases the levels of RIP1 and RIP3 in cultured myotubes. (B) Myotubes were
pre-incubated with 20 µM Nec-1 for 2h followed by treatment with 100 ng/ml
TWEAK for 48h. Representative phase contrast images presented here
demonstrate that treatment with Nec-1 considerably reduced TWEAK-induced
myotube cell death. Scale bar: 50 µM. (C) An LDH assay was performed to
quantify the cytotoxicity with respect to the RIP1 inhibitor, Nec-1. Interestingly, at
72h the Nec-1 treated group displayed a substantial decrease in cytotoxicity
relative to TWEAK-treated controls. N=3 in each group. *p < 0.05, values
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significantly different from control cultures. #p < 0.05, values significantly different
from TWEAK-treated cultures incubated without Nec-1 peptide.
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FIGURE 3.6. TWEAK induces oxidative stress in cultured myotubes.
Myotubes were treated with the indicated amounts of TWEAK for 24h and
stained with the CellROX reagent. The CellROX reagent is non-fluorescent while
in a reduced state and subsequently exhibits bright fluorescence when oxidized
by ROS. Representative images present here demonstrate that 100 ng/ml of
TWEAK induced significant oxidative stress. Scale: 25 µm.
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FIGURE 3.7. TWEAK perturbs the expression of various oxidant and
antioxidant molecules in cultured myotubes. Myotubes were treated with 100
ng/ml of TWEAK for 48h and mRNA levels were measured by QRT-PCR. There
was a decrease in all of the antioxidant enzymes except SOD1 with a concurrent
increase in the oxidant enzymes, XDH and NOX2. These results indicate that
TWEAK induces oxidative stress through modulating the levels of various oxidant
and anti-oxidant molecules. N=3 in each group. *p < 0.05, values significantly
different from control cultures.
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FIGURE 3.8. N-acetyl cysteine (NAC) inhibits TWEAK-induced cell death in
myotube cultures. Fully differentiated myotubes were pretreated with the
indicated concentrations of NAC for 2h and subsequently treated with 100 ng/ml
of TWEAK for 72h. An LDH assay was performed to quantify the cytotoxicity with
respect to NAC. At the lower concentration, NAC did not reduce cytotoxicity
relative to the myotubes treated with TWEAK alone. However, the higher
concentration of NAC significantly reduced cytotoxicity in TWEAK-treated
myotubes, but still remained high relative to untreated myotubes. *p < 0.05,
values significantly different from corresponding cultures incubated without
TWEAK. #p < 0.05, values significantly different from TWEAK-treated cultures
incubated without or with 0.1mM NAC.
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FIGURE 3.9. Absence of TWEAK perturbs the antioxidant and oxidant
mRNA expression after denervation. A 2-3 mm section of sciatic nerve was
removed from the hind limb of 2 month old wild-type and TWEAK-KO mice. A
sham incision was made on the contralateral hind limb and then sutured
accordingly. The mice were allowed to recover for three days and then
euthanized. The gastrocnemius muscle was isolated and used to measure
relative mRNA levels of various oxidant and antioxidant molecules by performing
QRT-PCR assay. (A) Relative mRNA levels of SOD1, SOD2, SOD3, GPx1,
GPx3, XDH and NOX2 in control and 3d denervated muscle of wild-type mice.
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Results demonstrate that the mRNA levels of all these molecules except SOD2 is
increased in denervated muscle compared to contralateral undenervated muscle.
(B) Relative mRNA levels of SOD1, SOD2, SOD3, GPx1, GPx3, XDH and NOX2
in control and 3d denervated muscle of TWEAK-KO mice. Interestingly, there
was no major change in mRNA levels of all these molecules in denervated
muscle of compared to contralateral undenervated muscle of TWEAK-KO mice
suggesting that TWEAK is involved in perturbing the expression of various
oxidant and antioxidant molecules in skeletal muscle upon denervation.
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CHAPTER 4: CONCLUSIONS AND FUTURE WORK
This chapter summarizes the work presented in this thesis and discusses its
implications in understanding the mechanisms of TWEAK-induced skeletal
muscle loss. It also highlights the significance of the findings obtained throughout
this thesis while acknowledging the limitations in implementing such findings in
future research.

Review of thesis
Skeletal muscle fibers are syncytia which arise from the fusion of myoblasts
during development. Loss of skeletal muscle mass is a devastating consequence
of a large number of chronic disease states such as cancer, diabetes, chronic
heart failure, chronic obstructive pulmonary disease, AIDS, high-dose
glucocorticoid therapy, renal failure, burn injury, and cystic fibrosis. Moreover,
prolonged inactivity that occurs during unloading, immobilization, microgravity,
bed rest, or nerve injury also results in the loss of skeletal muscle mass.
The TWEAK-Fn14 system has now emerged as a major regulator of
skeletal muscle mass. As summarized in Chapter 1, the understanding of the role
and mechanisms of activation of TWEAK-Fn14 system in skeletal muscle
development, regeneration, atrophy, oxidative metabolism, and regenerative
response has taken a quantum leap in recent years. Most of the studies have
shown that TWEAK causes deleterious effects leading to an overall deficit in
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skeletal muscle mass and strength. Furthermore, major progress has also been
made about the differential signaling potential of the TWEAK-Fn14 axis,
increasing appreciation of its complexity. This demands for a more thorough
investigation of its effects on skeletal muscle cells, especially in the context of
sustained TWEAK/Fn14 signaling so as to better understand its pathogenic roles
in settings of chronic muscle injury such as muscular dystrophy and skeletal
muscle atrophy in various catabolic conditions. TWEAK or Fn14 null mice are
viable and fertile and show no major abnormalities in naïve conditions. For this
reason, we believe the TWEAK-Fn14 system is among the most attractive drug
targets for the prevention of muscle loss. Since TWEAK is an extracellular
protein, TWEAK-dependent signaling can be blocked using a TWEAK
neutralizing antibody or soluble Fn14-Fc decoy protein, which can prevent
TWEAK binding to Fn14 receptors on cells.
To understand the mechanisms of action of TWEAK on skeletal muscle, I
focused my thesis on the cell survival aspect and oxidative stress. We have
found that TWEAK induces myotube cell death. The physiological significance of
TWEAK-induced muscle cell death is currently unknown. However, it is possible
that elevated levels of TWEAK contribute to muscle death especially in
conditions such as muscular dystrophy where the sarcolemma is already weak
and the inflammatory immune response is exacerbated. Moreover, TWEAK may
induce selective myonuclear apoptosis in myofibers leading to a reduced
myonuclear domain and a reduction in the size of the myofiber. Apoptosis has
been shown to play a role in skeletal muscle wasting in many conditions
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including denervation, aging, and some forms of muscular dystrophy. The results
presented in this thesis suggest that TWEAK can induce apoptosis in cultured
myotubes. Our results also suggest that both mitochondrial-dependent and
independent apoptotic pathways can be induced in myotubes upon treatment
with TWEAK. We have previously reported that TWEAK induces the activation of
various caspases in cultured myotubes which may contribute to muscle
proteolysis in various conditions75. Expanding on those studies, our results in the
present study suggest that TWEAK-induced activation of caspases can also lead
to myotube death. Our results have demonstrated that TWEAK-induced muscle
cell death is partially inhibited in the presence of a pan-caspase inhibitor.
In recent years, necroptosis has emerged as another form of programmed
cell death. Although there have not been many studies about the involvement of
necroptosis in skeletal muscle so far, it may be an important mechanism of
muscle cell death in various muscle degenerative disorders. While more
investigations are needed, our study provides initial evidence that the TWEAKFn14 system can induce necroptosis in myotubes. Indeed, we found that
necrostatin-1 inhibits TWEAK-induced cytotoxicity. Together, our findings provide
initial evidence that inhibition of TWEAK-Fn14 signaling can improve skeletal
muscle survival.
Oxidative stress is a major player in both the physiology and the
pathophysiology of skeletal muscle. Previous studies have shown that
proinflammatory cytokines induce the production of ROS in skeletal muscle
through distinct mechanisms. Oxidative stress, by itself, can be a stimulus for the
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activation of various proteolytic systems in skeletal muscle. Furthermore,
oxidative stress can produce irreversible changes in various cell types leading to
cell death. Our experiments have provided initial evidence that TWEAK induces
oxidative stress, which in part contributes to myotube death. Although the exact
mechanisms remain unknown, our experiments also suggest that TWEAK affects
the expression of various oxidant and antioxidant genes in skeletal muscle.
Future studies will determine how TWEAK is responsible for the development of
oxidative stress in atrophying skeletal muscle.

Contribution of thesis and future implementations
The work presented in this thesis provides additional mechanisms for TWEAKinduced skeletal muscle loss. These studies have wider application for skeletal
muscle disorders because TWEAK-Fn14 axis has been implicated not only in
skeletal muscle atrophy, but in the pathogenesis of many degenerative muscle
disorders as well. Additional studies will need to be conducted to dig deeper into
how TWEAK-Fn14, oxidative stress, and downstream effector pathways are
connected and modulated in a context-specific manner. A few ideas for future
implementations are mentioned below.
Mechanistic studies need to be performed to show how TWEAK-Fn14
signals via an alternative extrinsic pathway leading to apoptosis and/or
necroptosis. Since the Fn14 receptor lacks a DD, yet contains a TRAF-binding
domain, it remains unknown exactly how TWEAK signals these pathways. It
would be interesting to see which molecules interact with specific TRAFs and
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complex to initiate pro-apoptotic or pro-necroptotic pathways. This could be done
with the use of genetic and immunological techniques to further support the data
that we have shown here.
Additional studies on TWEAK and oxidative stress also need to be
conducted in cultured myotubes to determine the specific role that oxidative
stress plays in TWEAK-induced signaling. Monitoring ROS production and
relative mRNA levels of antioxidant vs. pro-oxidant levels at additional time points
from the start of TWEAK treatment to the late stages of TWEAK-induced
myotube atrophy may prove lucrative. Additionally, the use of pharmacological
antioxidant mimetics or pro-oxidant inhibitors may provide more insight into the
role of oxidative stress in response to TWEAK. These experiments could be
repeated using genetic approaches to knockout or upregulate some of the
important molecules and observe the impact on TWEAK-treated myotubes as
well.
Finally, applying the knowledge that we have gained from the in vitro
studies to in vivo models would provide further evidence for the role of oxidative
stress, apoptosis, and necroptosis with respect to TWEAK. Utilizing not only
TWEAK-KO mice, but also muscle-specific TWEAK-TG mice would provide
much more data to hone our findings and draw further conclusions. In addition to
the sciatic denervation model that was utilized in this study, it would be
interesting to use other models such as skeletal muscle injury, starvation, and
muscle disease models (Duchenne muscular dystrophy and Mdx mouse) to see
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if there are context-dependent alterations in TWEAK’s modulation of these
processes.

Limitations of future implementations
The thesis concludes that TWEAK is a potent inducer of oxidative stress in
skeletal muscle cells. In TWEAK’s initial characterization it was described as a
protein that did not induce apoptosis through the canonical death domain and it
was suggested that TWEAK signals apoptosis via an alternative entry point into
the caspase-mediated death cascade and was therefore coined as a “weak”
inducer of apoptosis42. This idea was further compounded by the initial
characterization of the Fn14 receptor in that it did not have the death domain
(DD) characteristic of many of the other TNFRSF members. Overall, this lead to
the thought that TWEAK had a more prominent role in growth and proliferation.
However, our studies suggest that TWEAK can induce apoptosis and necroptosis
as well, at least in cultured skeletal muscle cells with the possibility that oxidative
stress serves as the mechanistic switch between a pro-survival and a cell deathinducing role.
Initially, ROS were thought to be mediators of disease and high hopes
were placed on treating these diseases with high doses of exogenous
antioxidants. With mixed results, research in the years since has shown the
importance of ROS and redox signaling in normal physiology, possibly providing
a reason for the lack of positive results from these studies in various disease
models. The disruption to normal signaling could outweigh the perceived benefit
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of exogenous antioxidant supplementation. Targeting endogenous antioxidant
regulatory molecules through the use of pro-oxidants may prove more beneficial
than exogenous antioxidant supplementation by priming the cell’s inherent
defense pathways.
Currently, the methods for measuring oxidative stress rely on utilizing
fluorogenic reagents, measuring the ratio of reduced to oxidized molecules such
as glutathione, or measuring oxidative damage by looking at protein, lipid, and
DNA biomarkers to draw conclusions. One current problem is that these
fluorogenic probes are unable to distinguish between the different ROS, which
limits our ability to draw specific conclusions115. For example, being able to
determine the role of hydrogen peroxide versus peroxynitrate and being able to
see their subcellular localization would allow for a more thorough understanding
and allow researchers to pinpoint better therapeutic targets to treat disease. With
additional research efforts focused on understanding ROS and redox signaling,
more precise methodology and technology will ensue to allow us to study these
molecules and their effects in real-time.
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